As with metabolic syndrome–related disorders, numerous studies of a variety of cancers, in cultured cells as well as mouse models, have shown that pharmacologic or genetic inhibition of FABP4 diminishes cell proliferation, migration, and invasiveness (71, 127, 193). Here, FABP4 is linked to metabolic syndrome.